PRKAA1 and metabolic disease: As AMPK is suppressed by high glucose and lipids, and activated by metformin, the first line drug for type 2 diabetes, it is a well‐received therapeutic target for metabolic disorders.17 In fact, the activation of AMPK by pharmacological agents or exercise can alleviate hyperglycaemia and hyperlipidemia and enhance insulin sensitivity.18, 19, 20 More than this, recent studies have depicted the roles of AMPK in various other functions such as fibrosis, epithelial to mesenchymal transition (EMT), cancer growth and progression.17, 21, 22, 23